Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31701469 | 0.94 | DDB1 (0.46) | DDB1CRBNGPR119PIK3CAPRKDC | |
| SCHEMBL23540550 | 0.86 | DDB1 (0.48) | DDB1CRBNPIK3CAMTOR | |
| SCHEMBL31700605 | 0.86 | DDB1 (0.43) | DDB1CRBNGPR119PIK3CAPRKDC | |
| SCHEMBL23541274 | 0.86 | DDB1 (0.49) | DDB1CRBNPIK3CAMTOR | |
| SCHEMBL31702313 | 0.85 | DDB1 (0.51) | DDB1CRBNPIK3CAMTOR | |
| SCHEMBL26101870 | 0.83 | DDB1 (0.49) | DDB1CRBNGPR119PIK3CAPRKDC | |
| SCHEMBL23832613 | 0.82 | DDB1 (0.59) | DDB1CRBNGPR119PIK3CAPRKDC | |
| SCHEMBL26101041 | 0.82 | DDB1 (0.52) | DDB1CRBNPIK3CAPRKDCMTOR | |
| SCHEMBL22526076 | 0.81 | DDB1 (0.60) | DDB1CRBNPIK3CAPRKDCMTOR | |
| SCHEMBL31702237 | 0.81 | DDB1 (0.42) | DDB1CRBNGPR119PIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | DDB1 3966/4885CRBN 1627/4885GPR119 1280/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | DDB1 3708/4885CRBN 133/4885GPR119 610/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | DDB1 3966/4885CRBN 1627/4885GPR119 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.